跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
EZETIMIBE - ROSUVASTATIN SANDOZ 10 MG / 20 MG ezetimibe 10 mg tablets and rosuvastatin (as calcium) 20 mg tablets composite pack - TGA Drug Approval Details
Approvals
/
TGA
/
EZETIMIBE - ROSUVASTATIN SANDOZ 10 MG / 20 MG ezetimibe 10 mg tablets and rosuvastatin (as calcium) 20 mg tablets composite pack
Approved
STANDARD
EZETIMIBE - ROSUVASTATIN SANDOZ 10 MG / 20 MG ezetimibe 10 mg tablets and rosuvastatin (as calcium) 20 mg tablets composite pack
Sandoz Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 29, 2025
Approval ID
d26045fb01f708f4
Company
Sandoz Pty Ltd
Type
Standard
Approval Details
Approval Id
d26045fb01f708f4
Product Name
EZETIMIBE - ROSUVASTATIN SANDOZ 10 MG / 20 MG ezetimibe 10 mg tablets and rosuvastatin (as calcium) 20 mg tablets composite pack
Artg Id
318874
Artg Name
EZETIMIBE - ROSUVASTATIN SANDOZ 10 MG / 20 MG ezetimibe 10 mg tablets and rosuvastatin (as calcium) 20 mg tablets composite pack
Sponsor
Sandoz Pty Ltd
Company Detail Path
/organization/sandoz-pty-ltd
Artg Date
2022-07-07
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/a1e2b58e8737dd2a9cb1eef7cb2f796c.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/ef5964198b5b024ed277ba594f8c8edd.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 29, 2025
Approval ID
d26045fb01f708f4
Type
Standard
Back to TGA Approvals